Literature DB >> 28504208

PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.

Shira Ronen1, Daniel W Abbott1, Oleksandr Kravtsov1, Amrou Abdelkader1, Yayun Xu2, Anjishnu Banerjee2, Kenneth A Iczkowski3.   

Abstract

The presence and extent of cribriform pattern of prostate cancer portend recurrence and cancer death. The relative expressions within this morphology of the prognostically adverse loss of PTEN, and the downstream inactivation of cell cycle inhibitor p27/Kip1 had been uncertain. In this study, we examined 52 cases of cribriform cancer by immunohistochemistry for PTEN, p27, and CD44 variant (v)7/8, and a subset of 17 cases by chromogenic in situ hybridization (ISH) using probes for PTEN or CDKN1B (gene for p27). The fractions of epithelial pixels positive by immunohistochemistry and ISH were digitally assessed for benign acini, high-grade prostatic intraepithelial neoplasia, and 8 morphologic patterns of cancer. Immunostaining results demonstrated that (1) PTEN loss was significant for fused small acini, cribriform-central cells, small cribriform acini, and Gleason grade 5 cells in comparison with other acini; (2) p27 loss was significant only for cribriform-peripheral cells and borderline significant for fused small acini in comparison with benign acini; and (3) CD44v7/8 showed expression loss in cribriform-peripheral cells; other comparisons were not significant. ISH showed that cribriform cancer had significant PTEN loss normalized to benign acini (P<.02), whereas Gleason 3 cancer or fused small acini did not. With CDKN1B, the degree of signal loss among various cancer morphologies was insignificant. In conclusion, molecular disparities emerged between the fused small acini and cribriform patterns of Gleason 4 cancer. PTEN or p27 loss as prognostic factors demands distinct assessment in the varieties of Gleason 4 cancer, and in the biphenotypic peripheral versus central populations in cribriform structures.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD44; CDKN1B; Gleason grading; PTEN; Prostate cancer; p27

Mesh:

Substances:

Year:  2017        PMID: 28504208     DOI: 10.1016/j.humpath.2017.04.024

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance.

Authors:  Se Young Choi; Bumjin Lim; Yoon Soo Kyung; Yunlim Kim; Bong Min Kim; Byung Hee Jeon; Jae Chan Park; Young Woong Sohn; Jae Hyuk Lee; Ji-Hyun Uh; Seongsoo Jang; Choung-Soo Kim
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Authors:  Marc Gillard; Justin Lack; Andrea Pontier; Divya Gandla; David Hatcher; Adam G Sowalsky; Jose Rodriguez-Nieves; Donald Vander Griend; Gladell Paner; David VanderWeele
Journal:  Eur Urol Focus       Date:  2017-12-08

Review 3.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 4.  Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.

Authors:  Amanda B Hesterberg; Jennifer B Gordetsky; Paula J Hurley
Journal:  Urology       Date:  2021-05-28       Impact factor: 2.633

5.  miR‑17‑5p regulates the proliferation and apoptosis of human trabecular meshwork cells by targeting phosphatase and tensin homolog.

Authors:  Xiaoyuan Wang; Zhijian Li; Jie Bai; Wuqi Song; Fengmin Zhang
Journal:  Mol Med Rep       Date:  2019-02-20       Impact factor: 2.952

6.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

7.  EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN.

Authors:  Zhaoming Li; Ran Qiu; Xia Qiu; Tian Tian
Journal:  Oncotarget       Date:  2017-12-02

8.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

9.  Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.

Authors:  Jochen Rutz; Sarah Thaler; Sebastian Maxeiner; Felix K-H Chun; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

10.  Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.

Authors:  Tim Hansum; Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Susanne Osanto; Rob C M Pelger; Tom van Wezel; Henk van der Poel; Elise Bekers; Jozien Helleman; Sebastiaan Remmers; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2021-06-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.